Results 171 to 180 of about 3,148 (231)

Oxidizability of Atherogenic Low-Density Lipoprotein Subspecies in Severe Familial Hypercholesterolemia: Impact of Long-Term Low-Density Lipoprotein Apheresis

, 2000
Sylvie Lepage, Fabienne Nigon, Dominique Bonnefont–Rousselot, U. Assogba, Sylvie Goulinet, Laurent Chancharme, Jacques Delattre, Éric Bruckert, M. John Chapman   +8 more
openalex   +1 more source

The Effectiveness of Low-Density Lipoprotein/Fibrinogen Apheresis in Promoting Wound Healing of No-Option Chronic Limb-Threatening Ischemia Foot Ulcers with Wound, Ischemia, and Foot Infection (WIfI) Wound Grade 3: A Single-Center Retrospective Analysis

Miki Fujii, Hideyo Hirai, Rei Tomyo, Ryo Mizobuchi, Ai Omori, Rica Tanaka, Hiroshi Mizuno   +6 more
openalex   +1 more source

Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia. [PDF]

Eur J Med Res
Hafiane A, Ronca A, Incerti M, Rossi A, Manfredini M, Favari E.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Lipoprotein Apheresis

Endocrinology and Metabolism Clinics of North America, 2015
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients ...
Patrick M, Moriarty, Linda, Hemphill
  +10 more sources

Lipoprotein(a) apheresis

Current Opinion in Lipidology, 2016
Purpose of review Currently, different methods for extracorporeal elimination of atherogenic apolipoprotein B100 containing lipoprotein particles are used in clinical practice. Most of them effectively remove both lipoprotein(a) [Lp(a)] and LDL.
Olga I. Afanasieva, Marat V. Ezhov, Sergei N. Pokrovsky   +2 more
openaire   +2 more sources

Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease

Journal of Clinical Lipidology, 2019
Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD). In the United States, lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany uses LA therapy for patients with an Lp(a) > 60 mg/dL, normal low-density lipoprotein cholesterol (LDL-C) levels, and CVD.
Patrick M. Moriarty, Lauryn K. Gorby, Jessica V. Gray   +2 more
openaire   +3 more sources

Lipoprotein apheresis in Austria – Reduction of cardiovascular events by regular lipoprotein apheresis treatment

Atherosclerosis Supplements, 2019
In Austria, about 12 patients per 1 million inhabitants are treated currently with lipoprotein (LP-) apheresis. In 2016 it has been suggested, that about 5000 patients were treated worldwide with LP-apheresis, more than half of them in Germany. Regular LP-apheresis aims to decrease apolipoprotein B-rich lipoproteins and to reduce cardiovascular events.
Kurt Derfler, Helmut Sinzinger, Theresa Berent, Robert Berent   +3 more
openaire   +3 more sources

Lipoprotein apheresis: State of the art and novelties

Atherosclerosis Supplements, 2013
Lipoprotein apheresis (LA) is an extracorporeal technique which permits the unselective or specific removal of lipoproteins, namely Low Density Lipoproteins (LDL), as well as other apolipoprotein B100-containing lipoproteins from plasma. LA represents a selective upgrade (with both clinical and metabolic advantages) from conventional forms of ...
STEFANUTTI, Claudia, Ulrich Julius
openaire   +3 more sources

Lipoprotein apheresis

Current Opinion in Lipidology, 2010
Lipoprotein apheresis is being performed with increasing frequency, but better data collection and recording of clinical outcomes are needed. Setting up registries would facilitate this process.This review appraises recent articles that discuss the need for national registries and requirements for setting them up, the efficacy of lipoprotein apheresis ...
openaire   +2 more sources